FindTrial
Sign In

ALZ-801

DRUG2 trials

Sponsors

Alzheon Inc.

Conditions

APOE3/4) and at the Early stage of diseaseEarly Alzheimer's DiseaseSubjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4ages 50-80 years

Phase 2

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
CompletedNCT04693520
Alzheon Inc.Early Alzheimer's Disease
Start: 2020-09-30End: 2025-07-16Updated: 2025-12-18
A PHASE 2, SINGLE-ARM STUDY OF THE BIOMARKER EFFECTS OF ALZ-801 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE WHO ARE CARRIERS OF THE ε4 VARIANT OF THE APOLIPOPROTEIN E GENE (APOE4/4 or APOE3/4)
CompletedCTIS2024-515858-25-00
Alzheon Inc.ages 50-80 years, APOE3/4) and at the Early stage of disease, Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4
Start: 2020-09-30End: 2025-07-16Target: 85Updated: 2025-08-26

Related Papers

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
Drugs2026-09-01
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease
Clinical Pharmacokinetics2025-02-052 citations
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
Drugs2024-06-2023 citations
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
Drugs2024-06-207 citations